Technical Analysis for PGNX - Progenics Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade C 4.29 -7.74% -0.36
PGNX closed down 7.74 percent on Monday, May 20, 2019, on 74 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PGNX trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish -7.74%
MACD Bearish Centerline Cross Bearish -11.36%
50 DMA Support Bullish -11.36%
Oversold Stochastic Weakness -11.36%

Older signals for PGNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.
Medicine Chemistry Biotechnology Cancer Pain Imaging Solid Tumors Oncology Cancers Prostate Cancer Morphinans Cyclopropanes Neuroblastoma Phenols Adc Constipation Salix Pharmaceuticals
Is PGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.42
52 Week Low 3.62
Average Volume 1,186,014
200-Day Moving Average 5.3825
50-Day Moving Average 4.8196
20-Day Moving Average 4.968
10-Day Moving Average 4.843
Average True Range 0.2501
ADX 17.69
+DI 18.6269
-DI 30.5942
Chandelier Exit (Long, 3 ATRs ) 4.8097
Chandelier Exit (Short, 3 ATRs ) 5.0403
Upper Bollinger Band 5.4737
Lower Bollinger Band 4.4623
Percent B (%b) -0.17
BandWidth 20.358293
MACD Line -0.075
MACD Signal Line 0.0121
MACD Histogram -0.0871
Fundamentals Value
Market Cap 301.46 Million
Num Shares 70.3 Million
EPS -0.06
Price-to-Earnings (P/E) Ratio -71.50
Price-to-Sales 6.47
Price-to-Book 5.52
PEG Ratio -0.02
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.80
Resistance 3 (R3) 4.86 4.74 4.72
Resistance 2 (R2) 4.74 4.61 4.72 4.69
Resistance 1 (R1) 4.52 4.53 4.46 4.46 4.66
Pivot Point 4.40 4.40 4.38 4.38 4.40
Support 1 (S1) 4.18 4.27 4.12 4.12 3.92
Support 2 (S2) 4.06 4.19 4.04 3.89
Support 3 (S3) 3.84 4.06 3.87
Support 4 (S4) 3.78